drug
repurpos
offer
expedit
econom
rout
develop
new
clinic
therapeut
comparison
tradit
drug
develop
growthbas
highthroughput
screen
concomit
drug
repurpos
enabl
rapid
identif
new
therapeut
use
investig
drug
howev
tradit
method
compat
microorgan
abnorm
growth
pattern
staphylococcu
aureu
smallcoloni
variant
scv
scv
subpopul
auxotroph
key
compound
biosynthet
pathway
result
low
growth
rate
scv
format
also
associ
reduc
antibiot
suscept
scv
abil
revert
normal
cell
growth
state
thought
contribut
recurr
aureu
infect
thu
critic
need
identifi
antimicrobi
agent
potent
scv
order
effect
treat
chronic
infect
accordingli
describ
adapt
adenyl
kinas
ak
base
cell
death
report
assay
identifi
member
food
drug
administr
fda
approv
drug
librari
display
bactericid
activ
aureu
scv
four
librari
member
daunorubicin
ketoconazol
rifapentin
sitafloxacin
exhibit
potent
scv
bactericid
activ
stabl
aureu
scv
investig
show
sitafloxacin
potent
methicillinsuscept
resist
aureu
well
aureu
within
establish
biofilm
taken
togeth
result
demonstr
abil
use
ak
assay
screen
smallmolecul
librari
scv
bactericid
agent
highlight
therapeut
potenti
sitafloxacin
repurpos
treat
chronic
aureu
infect
associ
scv
andor
biofilm
growth
state
import
convent
antibiot
fail
success
treat
chronic
osteomyel
endocard
devicerel
airway
infect
recur
infect
associ
emerg
scv
recalcitr
convent
antibiot
studi
investig
antibiot
therapi
treat
scvrelat
infect
littl
success
emphas
need
identifi
novel
antimicrobi
drug
howev
drug
discoveri
costli
timeconsum
process
altern
strategi
drug
repurpos
could
identifi
fdaapprov
wellcharacter
drug
could
offlabel
util
treat
scv
studi
adapt
highthroughput
akbas
assay
identifi
fdaapprov
drug
daunorubicin
ketoconazol
rifapentin
sitafloxacin
display
antimicrobi
activ
aureu
scv
suggest
avenu
drug
repurpos
order
effect
treat
scvrelat
infect
addit
screen
paradigm
citat
trombetta
rp
dunman
pm
schwarz
em
kate
sl
awad
ha
highthroughput
screen
approach
repurpos
fdaapprov
drug
bactericid
applic
staphylococcu
aureu
smallcoloni
variant
msphere
easili
adapt
drugchem
librari
identifi
compound
bactericid
scv
keyword
staphylococcu
aureu
smallcoloni
variant
highthroughput
screen
drug
repurpos
chronic
infect
rug
discoveri
crucial
process
identifi
candid
compound
molecul
biolog
potenti
develop
clinic
effect
therapeut
howev
discoveri
process
costli
fraught
risk
frustrat
failur
associ
cost
success
drug
launch
reach
million
research
develop
expens
drug
take
year
develop
despit
huge
expenditur
nearli
drug
candid
make
phase
trial
fail
achiev
drug
approv
time
cost
high
failur
rate
drug
develop
prompt
pharmaceut
compani
pursu
altern
avenu
effect
therapeut
one
promis
avenu
drug
reposit
repurpos
process
discov
new
use
exist
drug
drug
food
drug
administr
fda
approv
repurpos
abil
go
directli
preclin
clinic
trial
reduc
lengthi
amount
time
preclin
drug
develop
thu
reduc
costli
risk
failur
numer
exampl
success
use
repurpos
approach
includ
screen
identifi
candid
therapi
zikv
infect
ebola
viru
diseas
alzheim
diseas
hepat
c
viru
commonli
appli
method
identifi
offlabel
effect
fdaapprov
drug
drug
repurpos
perform
highthroughput
screen
ht
drug
compound
librari
methodolog
especi
critic
context
chronic
bacteri
infect
due
rise
bacteri
resist
antibiot
drugresist
bacteri
strain
easili
screen
use
wholecel
bacteri
growth
assay
drug
compound
librari
howev
addit
drug
resist
chronic
infect
often
attribut
altern
bacteri
phenotyp
smallcoloni
variant
scv
scv
subpopul
bacteria
slower
metabol
thought
key
contributor
chronic
staphylococcu
aureu
infect
alter
growth
state
scv
character
low
growth
rate
reduc
coagulas
hemolyt
activ
small
coloni
size
agar
plate
absenc
pigment
antibiot
recalcitr
vari
auxotrophi
hemin
menadion
andor
thymidin
requir
normal
growth
abnorm
low
growth
rate
convent
wholecel
growthbas
assay
use
ht
practic
scv
urg
need
ht
methodolog
scv
quit
common
epidemiolog
standpoint
grow
appreci
role
reduc
growth
state
play
chronic
infect
osteomyel
endocard
devic
infect
soft
tissu
infect
airway
infect
instanc
staphylococc
scv
recov
prosthet
joint
infect
pji
cystic
fibrosi
case
scv
identif
diagnosi
particularli
difficult
scv
often
overlook
due
reduc
growth
rate
small
coloni
size
well
lack
pigment
reduc
coagulas
activ
lead
misidentif
coagulaseneg
staphylococci
recov
scv
physiolog
display
phenotyp
variat
patient
patient
moreov
aminoglycosid
clindamycin
fluoroquinolon
frontlin
therapi
treatment
aureu
infect
scv
recalcitr
drug
due
alter
metabol
prompt
numer
studi
defin
genet
determin
involv
reduc
suscept
scv
antibiot
associ
auxotroph
menadion
hemin
andor
thymidin
result
defici
electron
transport
menadion
hemin
andor
thymidyl
biosynthet
pathway
defici
metabol
pathway
result
lower
membran
potenti
reduc
metabol
explain
scv
abil
surviv
antibiot
treatment
addit
scv
abil
persist
intracellularli
within
nonphagocyt
cell
bone
epitheli
endotheli
cell
henc
avoid
hostimmun
respons
antibiot
treatment
abil
scv
revert
normal
coloni
phenotyp
ncp
also
add
evid
import
role
reoccurr
infect
restor
virul
lead
recurr
infect
thu
clinic
need
priorit
current
antibiot
reposit
drug
andor
identifi
novel
agent
effect
scv
prevent
relaps
infect
effect
treat
chronic
infect
object
studi
perform
highthroughput
screen
ht
fdaapprov
drug
librari
specif
identifi
candid
bactericid
ncp
biofilm
also
bactericid
mutat
smallcoloni
variant
strain
scv
harbor
hemb
delet
object
mind
set
adapt
recent
develop
valid
adenyl
kinas
ak
releas
report
assay
ht
platform
identifi
agent
display
bactericid
activ
toward
slowli
andor
nongrow
bacteri
popul
includ
scv
ht
recent
use
screen
fdaapprov
drug
librari
agent
display
bactericid
activ
pseudomona
aeruginosa
biofilm
identifi
compound
display
antibiofilm
activ
basi
assay
ak
ubiquit
intracellular
enzym
catalyz
convers
two
adp
molecul
atp
amp
releas
extracellularli
cell
death
extracellular
ak
releas
lyse
cell
subsequ
measur
use
commerci
toxilight
report
cocktail
base
atpdepend
bioluminesc
measur
ak
lonza
basel
switzerland
studi
demonstr
ak
releas
assay
scale
ht
food
drug
administr
fda
approv
drug
librari
contain
drug
candid
identifi
candid
bactericid
assay
hit
valid
character
antimicrobi
efficaci
wildtyp
aureu
strain
antibiofilm
activ
resist
frequenc
human
cell
cytotox
identif
screen
hit
bactericid
aureu
smallcoloni
variant
akbas
ht
assay
use
screen
selleck
librari
consist
fdaapprov
drug
candid
show
bactericid
activ
h
treatment
stabl
scv
aureu
strain
see
tabl
supplement
materi
screen
identifi
drug
display
increas
ak
signal
surpass
two
standard
deviat
overal
mean
ak
level
entir
librari
tabl
among
two
antibiot
rifapentin
antitubercular
agent
sitafloxacin
fluoroquinolon
identifi
remain
vari
therapeut
area
classif
rang
antifung
ketoconazol
anticanc
apatinib
daunorubicin
antivir
ammonium
glycyrrhizin
cidofovir
cardiac
relat
clonidin
hydrochlorid
furosemid
milrinon
inhibitor
sulbactam
proton
pump
inhibit
esomeprazol
antioxidantanthelmint
genistein
anesthet
mepivacain
muscl
relax
methocarbamol
antihistamin
mizolastin
antiangiogenicimmunomodul
pomalidomid
watersolubl
vitamin
pantothen
acid
sulfonamid
sulfamethazin
antipsychoticantidepress
amitriptylin
olanzapin
confirm
whether
increas
ak
signal
inde
correspond
bactericid
activ
drug
screen
hit
retest
antimicrobi
activ
use
quantit
microbiolog
plate
treat
candid
drug
drug
result
number
viabl
cfu
compar
mocktreat
cell
dimethyl
sulfoxid
dmso
four
drug
test
daunorubicin
ketoconazol
rifapentin
sitafloxacin
display
potent
antimicrobi
activ
result
reduct
viabl
scv
compar
mocktreat
cell
daunorubicin
anthracyclin
chemotherapi
agent
rifapentin
rifamycin
class
antibiot
sitafloxacin
fluoroquinolon
antibiot
yield
detect
viabl
bacteria
ketoconazol
imidazol
antifung
display
reduct
rel
mocktreat
control
fig
remain
hit
display
reduct
thu
consid
less
potent
classifi
lowprior
agent
investig
mic
valid
screen
hit
aureu
scv
ncp
strain
initi
mean
evalu
spectrum
antimicrobi
activ
four
highprior
hit
convent
mic
assay
perform
genet
divers
strain
aureu
includ
methicillinsuscept
aureu
mssa
strain
methicillinresist
aureu
mrsa
strain
scv
daunorubicin
ketoconazol
rifapentin
sitafloxacin
concentr
rang
gml
mic
result
compar
convent
aminoglycosid
gentamicin
tabl
commonli
use
local
deliveri
orthoped
infect
via
poli
methyl
methacryl
pmma
bone
cement
spacer
observ
increas
mic
gentamicin
scv
comparison
ncp
consist
previous
report
valu
reaffirm
scv
refractori
antibiot
rifapentin
sitafloxacin
mic
scv
strain
test
lower
gentamicin
daunorubicin
ketoconazol
tabl
suggest
may
repres
potent
option
treat
aureu
scvassoci
infect
antimicrobi
efficaci
valid
screen
hit
establish
aureu
biofilm
aureu
chronic
infect
also
associ
biofilm
format
compris
heterogen
popul
cell
ncp
scv
assess
antimicrobi
efficaci
identifi
candid
aureu
biofilm
grown
h
challeng
daunorubicin
ketoconazol
sitafloxacin
rifapentin
gentamicin
assess
biofilm
vulner
compound
briefli
biofilm
grown
polystyren
peg
use
minimum
biofilm
erad
concentr
mbec
assay
innovotech
edmonton
canada
growth
medium
supplement
volvol
human
plasma
enabl
robust
biofilm
form
h
fig
c
establish
biofilm
challeng
daunorubicin
ketoconazol
sitafloxacin
rifapentin
gentamicin
h
concentr
rang
gml
peg
sonic
recoveri
plate
serial
dilut
plate
result
cfu
enumer
sitafloxa
cin
demonstr
reduct
recov
biofilmassoci
cfu
comparison
mocktreat
growth
control
dmso
concentr
gml
fig
addit
compar
gentamicin
treatment
control
sitafloxacin
display
signific
reduct
viabl
bacteria
within
biofilm
concentr
gentamicin
rifapentin
induc
reduct
recov
biofilmassoci
cfu
concentr
test
daunorubicin
result
reduct
recov
biofilmassoci
cfu
concentr
gml
ketoconazol
fail
demonstr
signific
bactericid
activ
aureu
biofilm
entir
rang
concentr
test
mammalian
cytotox
valid
screen
hit
assess
detriment
effect
drug
candid
mammalian
cell
establish
therapeut
window
compar
toxic
concentr
identifi
mic
cytotox
daunorubicin
ketoconazol
rifapentin
sitafloxacin
gentamicin
measur
use
xtt
prolifer
assay
involv
treat
human
embryon
kidney
hek
cell
candid
drug
concentr
rang
gml
h
result
show
gentamicin
induc
signific
cytotox
effect
rang
concentr
test
cell
viabil
fig
sitafloxacin
rifapentin
display
least
cytotox
effect
candid
test
signific
dosedepend
cytotox
effect
observ
concentr
rang
gml
gml
respect
fig
e
wherea
daunorubicin
ketoconazol
demonstr
signific
cytotox
effect
comparison
mocktreat
cell
concentr
rang
gml
gml
respect
fig
c
therapeut
ratio
defin
ratio
lowest
concentr
caus
cytotox
mic
test
aureu
strain
calcul
daunorubicin
ketoconazol
rifapentin
sitafloxacin
tabl
consist
observ
daunorubicin
ketoconazol
lowest
therapeut
ratio
respect
wherea
rifapentin
sitafloxacin
highest
therapeut
ratio
antimicrobi
activ
human
serum
spontan
resist
frequenc
antimicrobi
activ
human
serum
also
evalu
investig
bioactiv
drug
presenc
serum
protein
mic
gener
increas
reflect
decreas
bactericid
activ
ketoconazol
rifapentin
sitafloxacin
gentamicin
presenc
human
serum
respect
tabl
howev
chang
observ
daunorubicin
presenc
human
serum
indic
serum
protein
affect
bactericid
activ
although
sitafloxacin
demonstr
serum
inactiv
liabil
increas
mic
mic
serum
gml
still
clinic
control
gentamicin
mic
gml
regular
muellerhinton
medium
well
within
therapeut
window
demonstr
bactericid
potenc
safeti
either
set
spontan
resist
frequenc
also
measur
mic
daunorubicin
ketoconazol
rifapentin
sitafloxacin
well
rifampin
investig
develop
resist
mutant
subject
drug
rifampin
use
control
known
antibiot
readili
induc
aureu
resist
mutant
ketoconazol
highest
frequenc
resist
order
either
mic
tabl
rifapentin
rifampin
similar
spontan
resist
frequenc
order
mic
howev
sitafloxacin
similar
equival
resist
frequenc
rifapentin
rifampin
mic
demonstr
order
magnitud
higher
resist
frequenc
mic
daunorubicin
yield
detect
level
resist
mutant
mic
data
suggest
rifapentin
sitafloxacin
equival
rifampin
induct
resist
mutant
ketoconazol
like
produc
resist
mutant
monotherapi
drug
result
incid
resist
mutant
howev
addit
supplement
drug
vancomycin
combin
therapi
reduc
resist
aureu
scv
clinic
challeng
due
associ
recurr
antibioticresist
infect
implantassoci
osteomyel
convent
therapeut
treatment
util
antibiot
aminoglycosid
decreas
potenc
scv
exampl
local
deliveri
antibiot
via
pmma
bone
cement
spacer
laden
gentamicin
fail
erad
scv
fig
cytotox
gentamicin
daunorubicin
ketoconazol
rifapentin
sitafloxacin
human
embryon
kidney
hek
cell
gentamicin
valid
screen
hit
screen
cytotox
effect
concentr
mgml
hek
cell
use
xtt
prolifer
assay
signific
judg
effect
drug
concentr
versu
mocktreat
control
anova
sidak
test
post
hoc
comparison
indic
p
indic
p
indic
p
indic
p
n
data
present
mean
standard
deviat
neg
control
mgml
zinc
pyrithion
fdaapprov
drug
bactericid
aureu
scv
effect
prevent
reoccurr
infect
case
osteomyel
due
reduc
suscept
convent
antibiot
novel
drug
discoveri
develop
essenti
efficaci
treatment
scvrelat
chronic
infect
howev
drug
discoveri
notori
slow
expens
highrisk
process
poor
profit
uncertain
regulatori
requir
market
approv
slow
discoveri
initi
larg
pharmaceut
compani
led
critic
need
find
new
approach
new
antimicrobi
drug
develop
one
approach
drug
repurpos
enabl
expedit
effici
strategi
identifi
new
applic
approv
drug
treat
diseas
incident
newli
fdaapprov
drug
repurpos
agent
convent
highthroughput
screen
typic
use
wholecel
bacteri
growth
assay
make
screen
challeng
due
slow
abnorm
growth
characterist
scv
henc
studi
use
ak
releasebas
cell
death
report
assay
ht
fdaapprov
selleck
drug
librari
bactericid
activ
aureu
scv
demonstr
abil
screen
approach
identifi
fdaapprov
drug
daunorubicin
ketoconazol
rifapentin
sitafloxacin
bactericid
drug
aureu
scv
current
effort
aim
identifi
antibiot
effect
scv
investig
suscept
stabl
clinic
isol
sitedirect
scv
mutant
vitro
use
convent
mic
test
use
anim
model
infect
gener
studi
consist
shown
antibiot
includ
aminoglycosid
cation
compound
antifol
less
activ
scv
due
lower
membran
potenti
rel
ncp
addit
cellwallact
antibiot
antibiot
inhibit
protein
biosynthesi
shown
reduc
bactericid
activ
slowgrow
scv
yet
antibiot
belong
famili
rifamycin
fluoroquinolon
shown
effect
scv
vitro
demonstr
low
mic
rang
gml
gml
respect
furthermor
rifamycin
shown
efficaci
clear
intracellular
scv
well
reduc
bacteri
burden
acut
phase
longterm
osteomyel
murin
mode
potenc
rifamycin
fluoroquinolon
consist
result
ht
identifi
rifapentin
rifamycin
sitafloxacin
fluoroquinolon
bactericid
stabl
scv
hemb
mutant
although
rifapentin
sitafloxacin
belong
two
class
antibiot
gener
shown
promis
scv
first
time
two
specif
drug
identifi
directli
kill
scv
addit
screen
selleck
librari
investig
fdaapprov
antibiot
broad
spectrum
fdaapprov
drug
develop
therapeut
applic
enabl
us
identifi
two
nonantibiot
drug
bactericid
aureu
scv
dauno
rubicin
ketoconazol
incident
daunorubicin
anthracyclin
chemotherapi
agent
ketoconazol
imidazol
antifung
previous
shown
bactericid
mode
action
aureu
howev
first
studi
confirm
bactericid
effect
aureu
scv
daunorubicin
ketoconazol
rifapentin
sitafloxacin
vari
mic
aureu
scv
ncp
regardless
drug
mode
action
sitafloxacin
daunorubicin
inhibit
dna
synthesi
act
upon
type
ii
dna
topoisomeras
howev
mic
sitafloxacin
found
nearli
two
order
magnitud
lower
daunorubicin
differ
may
attribut
uptak
drug
scv
phenotyp
well
sitafloxacin
addit
mode
action
dna
gyras
warrant
investig
sitafloxacin
efficaci
scv
rifapentin
similar
scv
mic
gml
regard
sitafloxacin
even
though
mode
action
inhibit
bacteri
rna
polymeras
ketoconazol
highest
mic
consist
inhibit
sterol
synthesi
effect
antifung
therapi
howev
regard
aureu
imidazol
antifung
induc
intracellular
reactiv
oxygen
speci
product
yet
despit
differ
mode
action
synergi
identifi
drug
observ
fraction
inhibitori
concentr
data
shown
drug
character
perform
assess
efficaci
four
drug
variou
aureu
strain
biofilm
cytotox
result
character
demonstr
sitafloxacin
bestperform
drug
due
low
mic
scv
variou
aureu
strain
potenc
establish
biofilm
low
cytotox
howev
antibiot
compar
spontan
resist
frequenc
rifampin
known
produc
resist
mutant
clinic
treat
monotherapi
suggest
need
use
combin
therapi
mitig
issu
sitafloxacin
develop
japan
approv
treat
respiratori
urinari
tract
infect
show
sitafloxacin
efficaci
scv
biofilm
report
signific
sinc
implantassoci
osteomyel
chronic
infect
associ
scv
biofilm
thu
propos
repurpos
approach
use
ak
releas
assay
basi
ht
effect
approach
identifi
new
use
approv
drug
treatment
infect
includ
scv
exampl
repurpos
sitafloxacin
orthoped
infect
could
prove
valuabl
potenti
efficaci
treatment
implantassoci
osteomyel
approach
decid
advantag
save
money
time
oppos
novel
drug
develop
full
potenti
assay
ht
tool
scalabl
larg
drug
novel
chemic
librari
screen
lab
strain
also
variou
clinic
isol
scv
strain
associ
mani
chronic
infect
result
studi
serv
foundat
develop
potent
therapi
combat
recurr
infect
high
therapeut
ratio
sitafloxacin
rifapentin
could
serv
basi
refin
pharmacophor
structur
drug
increas
bactericid
potenc
extend
screen
paradigm
interrog
novel
smallmolecul
drug
candid
develop
new
class
antimicrobi
effect
combat
scv
recurr
infect
howev
studi
limit
one
caveat
use
ak
assay
screen
scv
found
identifi
hit
reduct
scv
result
falseposit
hit
rate
rate
could
decreas
refin
select
criteria
posit
hit
howev
would
come
risk
miss
posit
hit
identif
addit
identifi
hit
associ
lytic
cell
death
compound
associ
nonlyt
cell
death
would
miss
limit
studi
one
stabl
scv
mutant
use
screen
purpos
clinic
recov
scv
heterogen
popul
vari
characterist
antibiot
suscept
base
auxotroph
distinct
growth
factor
result
metabol
pathway
defici
affect
antibiot
suscept
recov
scv
therefor
futur
work
investig
potenc
identifi
hit
stabl
scv
mutant
ie
well
clinic
isol
summari
util
ak
releas
cytotox
assaybas
ht
identifi
drug
daunorubicin
ketoconazol
rifapentin
sitafloxacin
display
bactericid
potenc
stabl
scv
strain
identif
drug
demonstr
use
approach
identifi
bactericid
agent
scv
provid
strategi
drug
repurpos
treat
chronic
infect
associ
aureu
scv
among
drug
sitafloxacin
display
highest
potenti
treat
infect
due
high
therapeut
ratio
signific
effect
aureu
biofilm
comparison
gentamicin
clinic
standard
treat
osteomyel
futur
studi
continu
screen
drug
chemic
librari
use
ak
screen
scv
also
investig
efficaci
safeti
sitafloxacin
combin
clinic
use
antibiot
treatment
establish
implantassoci
osteomyel
preclin
rodent
model
chemic
compound
librari
librari
consist
fdaapprov
drug
purchas
selleck
chemic
houston
tx
daunorubicin
sitafloxacin
rifapentin
also
obtain
selleck
chemic
ketoconazol
gentamicin
sulfat
purchas
alfaaesar
ward
hill
antimicrobi
stock
prepar
accord
recommend
store
adenyl
kinas
bactericid
report
assay
fdaapprov
drug
librari
screen
scv
use
ak
ht
ak
assay
carri
previous
describ
modif
account
slower
growth
briefli
cultur
stabl
aureu
scv
strain
grown
mh
medium
rpm
use
inocul
dilut
ml
mh
medium
grown
optic
densiti
od
correspond
cfuml
cell
pellet
centrifug
rpm
min
resuspend
ml
mh
medium
cfuml
fifti
microlit
cell
solut
ad
l
mh
medium
l
drug
drug
librari
ad
well
whitewal
microtit
plate
corn
life
scienc
durham
nc
achiev
concentr
higher
screen
concentr
use
comparison
previou
studi
ensur
hit
identif
resili
natur
scv
plate
incub
h
afterward
l
toxilight
ak
reagent
lonza
basel
switzerland
ad
well
incub
min
luminesc
measur
use
spectramax
plate
reader
assay
perform
duplic
hit
identifi
threshold
luminesc
valu
normal
mocktreat
growth
control
valu
greater
equal
overal
mean
plu
two
time
standard
deviat
compens
increas
nois
certain
plate
threshold
appli
independ
select
plate
addit
hit
select
remov
select
plate
increas
nois
rel
overal
data
secondari
cell
viabil
assay
cfuml
cell
treat
identifi
hit
h
enumer
plate
distinguish
primari
assay
screen
artifact
valid
hit
antimicrobi
suscept
test
mic
test
perform
accord
clinic
laboratori
standard
institut
clsi
guidelin
short
well
plate
falcon
corn
life
scienc
durham
nc
inocul
cfuml
either
contain
serial
dilut
indic
antimicrobi
rang
gml
mh
media
assay
also
perform
presenc
human
serum
instead
mh
media
mic
defin
lowest
concentr
antimicrobi
visibl
bacteri
growth
well
human
serum
judg
mic
difficult
due
minim
growth
opaqu
media
respect
mic
defin
compound
demonstr
cfuml
decreas
cell
growth
inhibit
rel
dimethyl
sulfoxid
dmso
mocktreat
cell
mic
confirm
repeat
test
duplic
spontan
resist
frequenc
determin
daunorubicin
ketoconazol
rifapentin
sitafloxacin
rifampin
gentamicin
exponentialphas
cultur
aureu
od
concentr
cfuml
centrifug
g
min
ml
cultur
resuspend
l
concentr
cell
suspens
plate
mh
agar
determin
start
inoculum
plate
supplement
mic
daunorubicin
ketoconazol
rifapentin
sitafloxacin
rifampin
resist
frequenc
determin
number
resist
coloni
divid
total
cfu
inoculum
test
perform
duplic
biofilm
suscept
assay
establish
biofilm
test
suscept
valid
ht
hit
gentamicin
clinic
relev
control
use
minimum
biofilm
erad
concentr
mbec
physiolog
genet
p
g
plate
innovotech
edmonton
canada
previous
establish
minor
modif
briefli
overnight
cultur
adjust
cfuml
tsb
supplement
volvol
pool
human
plasma
innov
research
novi
mi
ad
individu
well
mbec
plate
volum
l
plate
incub
h
shake
rpm
incub
peg
lid
transfer
microtit
plate
contain
l
pb
wash
min
shake
rpm
wash
peg
lid
transfer
antimicrobi
challeng
plate
contain
serial
dilut
l
gentamicin
valid
ht
drug
tsb
challeng
biofilm
incub
addit
h
shake
rpm
follow
day
peg
wash
transfer
bacteri
recoveri
plate
contain
l
tsb
sonic
hz
use
branson
ultrason
cleaner
bacteri
viabil
immedi
assess
use
l
recoveri
plate
enumer
plate
serial
dilut
tsb
agar
scan
electron
microscopi
sem
also
implement
qualit
assess
growth
biofilm
h
growth
control
peg
broken
fix
paraformaldehyd
cacodyl
buffer
postfix
osmium
tetroxid
dehydr
gold
sputter
coat
prior
imag
gentamicin
compar
valid
hit
test
concentr
twoway
anova
sidak
test
multipl
comparison
differ
consid
signific
p
test
perform
triplic
cytotox
cytotox
effect
valid
ht
hit
gentamicin
character
hek
cell
use
xtt
phenylamino
carbonyl
hydroxid
cell
prolifer
assay
sigmaaldrich
st
loui
mo
short
hek
cell
maintain
dulbecco
minimum
essenti
media
dmem
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
penstr
glutamax
seed
microtit
plate
cellswel
allow
attach
overnight
h
co
cell
treat
ht
valid
hit
gentamicin
dilut
dmem
without
phenol
red
supplement
fb
penstr
incub
h
cell
rins
pb
medium
replac
dmem
without
phenol
red
supplement
fb
penstr
l
xttpm
ratio
cell
media
cell
incub
addit
h
absorb
measur
nm
use
biotek
synergi
mx
plate
reader
toxic
repres
percent
cell
viabil
rel
mocktreat
growth
control
assay
perform
triplic
gentamicin
compar
valid
hit
test
concentr
twoway
anova
sidak
test
multipl
comparison
differ
consid
signific
p
supplement
materi
articl
may
found
http
tabl
xlsx
file
mb
